We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
Under the new initiative, each company takes on a defined role across the recycling chain
For the full year, standalone gross revenue crossed Rs. 1,700 crore
The company highlighted continued demand strength and pricing resilience despite global disruptions
The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
